Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
The greatest benefits of encorafenib plus binimetinib were observed in patients with evidence of high TMB and/or tumor immune infiltration, suggesting potential immune contributions to efficacy, which were not observed with vemurafenib. BRAF V600 detectability in ctDNA appears to have utility as a marker of prognosis and response in this population.
Authors
- Ivana Krajsová (ORCID: https://orcid.org/0000-0002-1599-6424)
- Tao Xie (ORCID: https://orcid.org/0000-0002-0580-6877)
- Hedieh Saffari
- Khyati N. Shah (ORCID: https://orcid.org/0000-0002-2510-803X)
- M. Mandala
- Phineas T. Hamilton (ORCID: https://orcid.org/0000-0001-6993-8505)
- S. Deng
- P. Ascierto
- Caroline Robert
- Craig B. Davis (ORCID: https://orcid.org/0000-0002-1703-451X)
- Naoya Yamazaki (ORCID: https://orcid.org/0000-0002-9158-5686)
- Nuzhat I. Pathan
- Dirk Schadendorf
- Jan Willem B. de Groot (ORCID: https://orcid.org/0000-0002-1043-5011)
- Carmen Loquai
- Ana Arance
- Keith Flaherty
- Helen J. Gogas
- Reinhard Dummer
- Gabriella Liszkay
- Claus Garbe
- Alessandra di Pietro
Institutions
- Pfizer (United States) (US)
- National and Kapodistrian University of Athens (GR)
- University of Perugia (IT)
- Université Paris-Saclay (FR)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Institut Gustave Roussy (FR)
- Massachusetts General Hospital (US)
- University Hospital of Zurich (CH)
- Hospital Clínic de Barcelona (ES)
- Essen University Hospital (DE)
- National Institute of Oncology (HU)
- University Children's Hospital Tübingen (DE)
- Frontier Science Foundation-Hellas (GR)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Pfizer (Italy) (IT)
- Isala (NL)
- Center for Cancer Research (US)
- Tokyo National Hospital (JP)
- Fachklinik Hornheide (DE)
- West German Heart and Vascular Center Essen (DE)
- General University Hospital in Prague (CZ)
- University of Duisburg-Essen (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3262
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Array BioPharma